Orkla: Zero Organic Growth in the Controlled Portfolio, Jotun Operating Profit Up 21%, and a 21% NAV Discount at NOK 97.10

The other important asset-marking event has already occurred. Orkla India filed its draft red herring prospectus on 10 June 2025. The October 2025 prospectus showed Orkla Asia Pacific with 90% of Orkla India before the offer and the Meeran family with 10%; the IPO was entirely an offer for sale, with no fresh primary capital raised by Orkla India. Orkla Asia Pacific offered 20.56 million shares, reducing Orkla's economic interest to about 75% after completion. Orkla India then listed on the NSE and BSE in November 2025.

That listing has produced a more sober valuation signal than the pre-IPO narrative implied. Orkla India's share closed at about INR 570.30 on 24 August 2026, versus the IPO price-band range of INR 695–730. Its equity market value was roughly INR 78.1 billion, or about NOK 7.6 billion using an approximate 24–25 August conversion of INR 10.29 per NOK; Orkla's 75% interest had a visible quoted value of about NOK 5.7 billion. This public price is particularly useful because it prevents an analyst from assigning India an unchallenged “emerging-market growth” premium.

Operationally, India deserves neither dismissal nor a heroic multiple. Q2 organic growth was 9.7%; stripping out a NOK 6 million prior-year government grant, organic growth was about 11%, including 1.7% volume growth. Yet underlying adjusted EBIT fell 4.1%; grant-adjusted growth was only 0.7%, because higher selling prices and volume were offset by spending to build digital-channel capabilities. The margin fell 2.3 percentage points to 15.8%. On an H1 basis, stripping out a larger NOK 33 million 2025 grant makes the picture better: organic growth was 8.5% and underlying EBIT growth 7.9%. The verdict is that India remains a credible growth asset, while the IPO market has correctly demanded evidence that revenue growth converts into profit.

The long business history explains why Orkla is back in investment-company form. Its roots are in mining at Løkken from 1654; Orkla Grube-Aktiebolag was established in 1904 and the company listed in 1929. The 1986 merger with Borregaard brought consumer brands into the group, the 1991 Nora merger deepened the Nordic branded-goods position, and subsequent decades took Orkla through brewing, media, aluminium, renewable energy and financial investments before a 2011–13 portfolio unwind turned it into a focused branded-consumer group. In 2023 management changed the organising principle again, giving independent portfolio companies greater accountability and describing Orkla explicitly as an industrial investment company.

That history shows real capital-allocation capability, but not flawless capital allocation. Orkla has repeatedly reshaped itself rather than preserving a structure past its economic usefulness. It sold Carlsberg Breweries, media, industrial assets, REC and Borregaard as strategic priorities changed; more recently it sold the hydropower portfolio at an enterprise value around NOK 6.1 billion, while continuing acquisitions such as BUBS, Denali Ingredients and the 2026 European Candy Group deal. Yet deal-level returns are not disclosed consistently enough to prove that the acquisition machine has generated excess returns across a full cycle. The current weakness in Health and Food Ingredients is a reminder that buying businesses and improving them are separate disciplines.

Capital returns also deserve scrutiny. Orkla paid NOK 6.00 per share in 2026, including NOK 2.00 explicitly described as additional to the ordinary dividend, and completed a NOK 4.0 billion buyback at an average NOK 106.5428 per share. At the 24 August price of NOK 97.10, the repurchase price is nearly 10% above the market. That does not prove the repurchase destroyed long-term value; it does show that investors should judge buybacks against intrinsic value rather than celebrate them automatically. Net interest-bearing liabilities increased to NOK 20.7 billion including leases at June 2026, equivalent to 2.0x trailing EBITDA, following large dividends and repurchases.

The stock itself reflects this tension. The 24 August close of NOK 97.10 was near the lower end of its recent 52-week range and about 14% below the 2025 year-end NOK 112.50. On the Q2 report day, 20 August, the stock closed around NOK 96.30, down 6.7% from the previous session, showing that the market treated flat controlled-company growth as a real disappointment despite Jotun's strength.

The bull-bear disagreement can be stated precisely. Bulls see a collection of branded assets whose controlled-company margins have improved considerably since 2023, a world-class coatings associate, an Indian business whose value is now externally observable, and management willing to sell, list, buy back and restructure assets. Bears see a holding company whose largest incremental source of earnings momentum is outside its control, whose core mature businesses are struggling for volume, whose Health restructuring is taking longer than hoped, and whose post-IPO India valuation has already compressed.

The qualitative portrait is: company in transition. Orkla has moved beyond the old conglomerate and beyond the “one integrated branded-goods company” model, but the investment-company architecture has not yet proved that independently run portfolio companies can consistently compound organic revenue, margins and return on capital without being carried by Jotun. The 2024–25 margin repair was real. Q2 2026 shows that the next stage requires revenue quality rather than another round of cost savings.

Vertical history, financial evolution, and capital-market narrative

Orkla's origins sit a long way from its present-day products. Mining began at Løkken Verk by the Orkla river in 1654. The corporate predecessor Orkla Grube-Aktiebolag was formed in 1904 to operate the mine; the company became publicly listed in 1929. By the 1940s Orkla was already developing an investment portfolio, and the Oslo office established in 1975 had an explicit mandate to expand the industrial platform.

The archival company history does not provide a reliably sourced 1929 IPO offer price or amount of primary capital raised, so this report does not invent one. The more important feature of that listing history is institutional: Orkla came to the stock market as an industrial asset owner long before it became a consumer-products company. Today's investment-company model is, in one sense, a return to the company's original capital-allocation identity.

The first decisive change came in 1986. Orkla merged with Borregaard, bringing businesses including Lilleborg and Stabburet and giving branded consumer goods a meaningful place alongside chemicals and investments. The 1991 merger with Nora Industrier then established the Nordic branded-goods platform; acquisitions of Procordia Food and Abba Seafood followed in 1995. Orkla simultaneously expanded elsewhere, including brewing, media and eventually aluminium and solar investments.

That produced the first major strategic paradox. Between 1986 and 2003 Orkla had an increasingly branded-goods-oriented identity, but from 2004 the group diversified again: it sold its Carlsberg Breweries stake while buying Elkem, Sapa and a major interest in REC. Orkla's own 2011 investor material later acknowledged that branded goods had become a much smaller share of group revenue. The portfolio had become sprawling enough that operational and capital-market narratives were difficult to reconcile.

The global financial crisis exposed that complexity. Solar and industrial exposures proved more cyclical than the consumer franchise, while leverage and capital tied up in disparate assets constrained strategic freedom. Management began unwinding the structure. Elkem Silicon-related was sold for roughly NOK 13 billion; the financial-share portfolio was reduced; REC was ultimately exited; and Borregaard was carved out and listed in October 2012 as Orkla explicitly described itself as becoming a focused branded-goods portfolio company.

The 2011–13 turn genuinely changed Orkla's fate. The market was no longer being asked to value solar, aluminium, media, financial investments and ketchup inside one conglomerate. The branded-goods identity became the organising principle. In September 2013 Orkla publicly described itself as having been transformed “from a conglomerate into a branded consumer goods company,” with its strategic emphasis on Nordic consumer brands.

The next decade was acquisition-driven. Orkla had entered India through MTR Foods in 2007, paying NOK 482 million. It bought Rieber & Søn for about NOK 6.1 billion in 2013, Cederroth for about NOK 1.84 billion in 2015 and Hamé for about NOK 1.62 billion in 2016. Later deals broadened the model beyond supermarket packaged food: Kotipizza in 2019, NutraQ and New York Pizza in 2021, Denali Ingredients and BUBS in 2023.

This period made Orkla more defensive but also more acquisition-dependent. The consumer businesses benefited from local brand recognition and Nordic distribution, yet the portfolio accumulated different growth profiles, geographic exposures and operating models. Food ingredients is a B2B ingredient platform. European Pizza mixes franchise economics with wholesale supply. Health combines supplements, personal care and direct-to-consumer activity. India has different demographics and channel development from Norway or Sweden. The conceptual problem gradually returned: “branded consumer goods” was broad enough to describe a portfolio, but not broad enough to make the portfolio operationally homogeneous.

Inflation in 2021–22 exposed the limits of the integrated model. Orkla's 2021 revenue reached NOK 50.4 billion and adjusted EBIT NOK 6.15 billion, but 2022 brought steep raw-material, energy, freight and supply-chain costs. Revenue rose sharply to NOK 58.4 billion, much of it through pricing, while several consumer units suffered volume pressure and margin compression. Orkla Food Ingredients was relatively successful at revenue management; consumer-care operations experienced much sharper profitability deterioration.

The answer was the 2023 reorganisation into independently accountable portfolio companies. At its November 2023 Capital Markets Day, Orkla divided assets into “grow and build,” “anchor” and “transform or exit” groups. Food Ingredients, Health, India and European Pizza were among the build assets; Jotun, Foods and Snacks were anchors; Home & Personal Care, House Care and HSNG were among the assets expected to transform or face eventual exit.

This is the current stage of the story. The parent describes itself as an industrial investment company, while portfolio businesses have their own boards and management and can use group-level centres of excellence in areas such as innovation, consumer insight and sustainability. The attractions are clear: accountability becomes visible, weaker companies can no longer hide behind a single group presentation, and assets can be listed or sold independently. The cost is that corporate complexity remains substantial, and the economic payoff from the shared “centres of excellence” is not separately disclosed. There is no hard financial evidence that lets an investor assign a synergy premium to those functions.

The 2025 hydropower disposal reinforced the investment-company model. Orkla sold its hydropower portfolio at an enterprise value of approximately NOK 6.1 billion, converting a non-core industrial asset into financial capacity. It also disposed of Pierre Robert. In 2026 the portfolio companies remained active acquirers: Food Ingredients bought Vortella, Senna and Phoenix Brands and agreed additional transactions; Foods agreed to buy 40% of Go-Tan and 100% of TC Brød; Snacks agreed to acquire the European Candy Group at an enterprise value around NOK 2.3 billion to add capacity and support BUBS' European expansion.

The India IPO was the clearest expression of the new model. Orkla did not sell control. The offer was entirely secondary, meaning Orkla India itself did not receive fresh IPO capital, and Orkla retained roughly 75%. The transaction created a continuously observable price for one portfolio company without surrendering consolidation. This is useful for NAV discipline, although it introduces a persistent minority-interest claim: Orkla consolidates 100% of India's revenue and EBIT but economically owns only 75% of the equity.

The governance transition in 2026 was less planned. Stein Erik Hagen and his family had supplied a stable long-term ownership anchor through Canica. Following Hagen's death, Christer Kjos was elected board chair, with Jan Ole Stangeland joining the board. The Canica/Hagen-family shareholder agreement represented 25.41% of outstanding shares after the June capital reduction, preserving substantial family influence. Orkla's related-party disclosure says ordinary annual sales to Canica companies have been around NOK 20 million on market terms and identifies no material special transaction at 30 June 2026.

This concentration is better viewed as an alignment feature with a governance discount attached than as a pure governance problem. A quarter of the equity has an owner with a multi-decade horizon, but minority shareholders remain dependent on that owner and the board agreeing on the pace of asset sales, listings, buybacks and reinvestment.

The financial record shows why the structural shift initially received some credit.

The 2021, 2022 and 2023 figures span a period when Orkla still reported industrial and financial assets differently from today's portfolio structure; 2025 and 2026 also reflect the classification of hydropower as discontinued. They describe the economic journey better than a mechanically clean CAGR does. Revenue and adjusted EBIT never include Jotun; adjusted EPS does reflect Orkla's share of Jotun's profit.

The key economic pattern is pricing followed by margin repair. The 2021–22 inflation cycle lifted nominal sales but hurt margins in businesses unable to reprice fast enough. From 2023 through 2025 Orkla tightened portfolio priorities, cut costs and recovered pricing. At the 2023 Capital Markets Day, management set a 2024–26 target for consolidated portfolio companies of 8–10% annual underlying adjusted-EBIT growth, a 1.5–2.0 percentage-point margin improvement and ROCE rising from 10% in 2023 to 13% in 2026. By H1 2026 the rolling adjusted-EBIT margin had risen 1.5 points to 10.5% and ROCE reached 12.3%. Underlying EBIT had compounded at 12% across full-year 2024 and 2025.

Then 2026 turned. First-quarter organic growth was 4.9%, including 3.2% volume/mix, but underlying EBIT growth was only 3.0%. Q2 organic growth then fell to zero and underlying EBIT growth to 2.5%. The strategic margin target is largely delivered; the EBIT-growth target is slipping because the sales engine has slowed.

The Q2 mix makes the problem visible.

Jotun is excluded from every figure in this table. Sources: Orkla Q2 2026 segment disclosures.

Foods illustrates the tension between brand portfolio quality and mature-market demand. Prioritised categories still generated 1.4% volume/mix growth, but the mature portfolio declined and total volume/mix was -2.3%, with Denmark, Finland and Norway especially soft. The 0.6-point margin improvement came from mix, lower advertising and temporarily lower fixed costs. Some of that margin gain is operationally real; some is unlikely to repeat indefinitely.

Snacks looks healthier beneath the headline. Organic sales fell 1.1%, mainly because chocolate prices were reduced, while volume/mix was slightly positive. Chocolate volumes and margins recovered and BUBS continued expanding, including the US rollout. Underlying EBIT rose 10.4% and contribution margin widened substantially.

Food Ingredients is the clearest current operating drag. Bakery volumes fell, especially in Central and Eastern Europe, Plant Based suffered weak demand and mix, and higher operating costs pushed underlying EBIT down 6.3%. Its Q2 adjusted-EBIT margin of 7.6% sits well below the branded food and health businesses. Acquisitions may eventually improve the portfolio, but adding businesses while the underlying base is weak can disguise whether organic returns are improving.

Health has a different problem. Revenue is still growing, but higher operating costs, advertising and elevated omega-3 input prices have compressed profit. H1 underlying EBIT fell almost 20%. Management expects elevated costs until three production sites are closed, one by end-2026 and two by end-2027. This is closer to an execution/restructuring issue than a pure demand problem.

Home & Personal Care and House Care provide evidence that the portfolio-company model can work. Home & Personal Care's Q2 organic sales fell 2.5%, but cost-out measures raised underlying EBIT 8.2%, lifted the margin to 14.1%, and rolling ROCE reached 25.7%. House Care grew underlying EBIT 12.4% despite negative organic sales, through mix and cost management. The limitation is obvious: cost-out can defend earnings for a while, but repeated negative sales eventually catches up with profit.

Cash generation remains respectable, but the first half was weaker. H1 2026 cash flow from operations was NOK 2.07 billion versus NOK 2.45 billion a year earlier, and cash flow before capital allocation was NOK 1.57 billion versus NOK 1.78 billion. Net replacement investment was NOK 1.20 billion and expansion investment NOK 391 million. Acquisitions consumed NOK 666 million. Dividends and treasury-share purchases consumed NOK 8.18 billion.

The balance sheet consequently moved in the wrong direction, deliberately rather than accidentally. Net interest-bearing liabilities including leases increased from NOK 14.2 billion at end-2025 to NOK 20.7 billion by June, or 2.0x trailing EBITDA. Excluding leases, the figure was NOK 18.4 billion. Orkla still describes its financial position as robust, but the company has less room for another large simultaneous special dividend, buyback and acquisition wave without leverage moving higher.

The share-price narrative tracks these strategic stages. The stock ended 2009 at NOK 56.85 after recovering from the financial crisis while Orkla still carried industrial and solar complexity. The 2011–13 disposal programme shifted the market narrative from conglomerate to defensive branded goods. The inflation shock of 2021–22 then made margin recovery the dominant question. By the end of 2025 the share was NOK 112.50 after a year in which Orkla reported a 24.2% total shareholder return. In 2026 the narrative has rotated once more: investors now want evidence that the holding-company model can produce organic growth and asset-value realisation, rather than simply repair margins.

At NOK 97.10, trailing adjusted EPS of NOK 6.83 implies a headline P/E of about 14.2x. At the 2025 year-end price, the same EPS represented about 16.5x. These calculations include Jotun through adjusted earnings, which is valid for a P/E because both the equity price and earnings belong to Orkla shareholders; they should not be confused with an operating margin.

A precise long-run “P/E percentile” would be misleading because the asset mix and accounting perimeter have changed radically. Orkla in 2010, Orkla as a pure branded-goods group in 2016, and Orkla as an investment company in 2026 are economically different securities. A historical SOTP discount series is similarly unavailable: Orkla does not publish a continuously marked NAV, and Jotun has no public share price. The sensible historical comparison is strategic and asset-based rather than a false precision around a single multiple.

Business model, moat, industry, and horizontal competition

Orkla's controlled business machine begins with local brands. Foods sells familiar Nordic and Baltic packaged-food products into grocery and food-service channels. Snacks owns chocolate, biscuits and confectionery franchises, including the fast-growing BUBS brand. Food Ingredients supplies bakeries, ice-cream producers and other B2B customers. Health combines consumer health, supplements and wound/oral care. Home & Personal Care and House Care sell cleaning and household brands. European Pizza derives economics from franchise-store consumer sales plus wholesale distribution. India owns MTR and Eastern and sells spices, mixes, meals and other packaged foods into a structurally faster-growing market.

Jotun sits outside this operating machine. In 2025 it generated NOK 34.33 billion of its own revenue and NOK 7.08 billion of operating profit, a 20.6% operating margin. Orkla owns 42.7% but consolidates none of those sales or operating costs. Jotun is therefore economically comparable to an investment in an unlisted coatings company, not to an Orkla segment.

Cost structures differ a great deal from business to business. Foods, Snacks and household-care companies carry manufacturing plants, procurement, distribution, advertising and retailer promotions. Fixed manufacturing and overhead create operating leverage when volume improves, but the concentrated Nordic grocery channel gives retailers real bargaining power and increases the threat from private label. Orkla itself identifies retailer concentration and private-label development as competitive risks.

Food Ingredients is more exposed to industrial volume, input costs and mix. Its Q2 contribution ratio was only 29.8%, versus 40.3% in Foods, 44.1% in Snacks and 57.5% in Health. That lower contribution economics explains why relatively modest volume weakness can create a disproportionate EBIT decline.

Health has higher product gross margins but currently carries restructuring and marketing expenses. The 57.5% Q2 contribution ratio did not protect EBIT from a 5.8% underlying decline because operating costs and advertising rose and omega-3 raw materials remained expensive. This is an example of why brand gross margin alone is not a moat.

Three defensible moats stand out.

First is local brand density and route-to-market. Orkla owns brands embedded in Nordic consumption habits and has relationships with highly concentrated grocery retailers that would be expensive for a new entrant to reproduce. The evidence that the moat still works is that prioritised Foods categories grew volume even while mature categories declined, and Home & Personal Care gained market share in Norway in Q2 despite negative organic sales. The weakness is retailer power. A supplier can have a strong brand and still surrender economics through promotions, assortment decisions and private-label competition.

Second is capital and portfolio mobility. Orkla has repeatedly bought, sold, carved out and restructured assets over decades. It entered India with MTR in 2007; disposed of non-core industrial assets after 2011; built Food Ingredients through acquisition; bought NutraQ, New York Pizza, BUBS and Denali; sold hydropower; and listed India while retaining control. This ability is real. Whether it is a moat depends on future deal returns, which are less well proven.

Third is the Jotun interest. Economically it is a scarce asset: a 42.7% stake in an unlisted global coatings business with very strong margins, a net-cash balance sheet and wide exposure to Asian, marine and protective-coatings markets. Nordic Credit Rating's May 2026 analysis showed 2025 adjusted EBITDA of roughly NOK 8.0 billion and net cash around NOK 2.0 billion, while Jotun itself reported the 20.6% operating margin. Yet ownership of a strong associate is an asset-quality advantage rather than a competitive moat for Orkla Foods.

The claimed shared “centres of excellence” deserve less credit. Orkla says independent businesses can access group capabilities in innovation, sustainability and consumer insight. No separate return-on-investment measure shows what those centres add compared with their corporate cost. In valuation I treat the parent cost as a deduction and assign no synergy premium.

Management's recent execution is mixed but credible. Nils Selte's team delivered substantial 2024–25 margin improvement and a 12% two-year compound rate of underlying EBIT growth in the consolidated portfolio companies, ahead of the 8–10% strategic target over that period. The first half of 2026 has then fallen to 2.7%. Management deserves credit for identifying that slowdown rather than presenting flat growth as satisfactory.

Capital allocation is the harder test. The hydropower sale and India listing improved asset visibility. The NOK 4 billion buyback cut the share base appreciably, and 16.0 million shares were already cancelled in 2026, with remaining repurchased shares intended for cancellation subject to the 2027 AGM. But the average repurchase price of NOK 106.54 is above today's market, and leverage rose after the capital return. The record is rational, not obviously exceptional.

The family ownership structure supports patience. Canica and related Hagen-family interests control 25.41% under the shareholder arrangement. That reduces the risk of management optimising only for a quarterly earnings print, while raising the usual holding-company question: whether capital deployment serves all shareholders on identical economic terms. The related-party amounts disclosed to date are small compared with group scale.

Industry structure explains much of the current organic-growth weakness. Nordic branded grocery is mature. Population growth is modest, retail concentration is high, and the inflation cycle forced brands to take large price increases in 2022–24. Once those increases became embedded, consumers and retailers became more price-sensitive. That makes the post-inflation transition a price/volume trade-off: nominal price contribution falls while brands need volume to return before the next leg of earnings growth becomes durable. Orkla's Q2 data show exactly this tension across Foods and Snacks.

This makes Orkla partly defensive and partly cyclical. Everyday food and cleaning demand is relatively defensive; volumes and mix remain exposed to consumer purchasing power, retailer promotions and commodity-price cycles. Food Ingredients adds a more explicit B2B demand cycle. European Pizza adds restaurant traffic. India introduces a structural consumption-growth component. Jotun adds construction, marine, infrastructure and industrial-cycle exposure. The holding company is more economically diversified than a typical packaged-food stock, but less predictable as a result.

The recent consumer peers show what “good” currently looks like. Unilever reported 2025 turnover of EUR 50.5 billion, operating profit of EUR 9.0 billion and free cash flow of EUR 5.9 billion; its underlying operating margin reached 20.0%, and H1 2026 margin rose further to 20.3%. Danone's H1 2026 sales grew 3.5% like-for-like with 1.7% volume/mix growth and a 13.3% recurring operating margin. Nomad Foods, a more relevant European packaged-food stress comparison, reported H1 2026 revenue down 4.5%, organic revenue down 4.1% and adjusted EBITDA down 13.3%.

Using the 24 August 2026 EUR/NOK reference rate of EUR 1 = NOK 10.8645 and USD/NOK around 9.31, these scale differences are large.

Orkla figures exclude Jotun. Peer reporting definitions differ; EBITDA and EBIT margins are not interchangeable. Sources: issuer disclosures.

What the peers show matters more than the raw numbers. Unilever has become a globally concentrated owner of large “power brands,” with marketing scale and a 20% underlying operating margin that Orkla's fragmented local portfolio cannot match. Danone is narrower by category, centred on dairy, nutrition and hydration, and currently combines mid-single-digit organic growth with a 13%-plus recurring margin. Nomad is geographically closer to Orkla's European packaged-food exposure and shows what happens when volume contraction meets input inflation: EBITDA can fall much faster than revenue.

Orkla's niche is local-market density rather than global brand scale. That can produce good returns in small markets, but it does not justify applying Unilever's margin or valuation to Orkla Foods. Conversely, Orkla's India and Jotun assets give it growth exposures that a pure Nordic packaged-food multiple would miss.

Jotun deserves an entirely different comparison set. Its 2025 operating revenue was NOK 34.3 billion and operating margin 20.6%. PPG generated USD 15.9 billion, roughly NOK 148 billion at the referenced exchange rate, of 2025 sales and reported a 19% segment EBITDA margin; Q2 2026 organic sales rose 4%. AkzoNobel's Q2 2026 adjusted EBITDA margin was 15.4%.

Definitions differ in ways that matter. Jotun's 20.6% figure is operating profit rather than EBITDA, which makes the profitability comparison particularly strong, but not mathematically identical.

Jotun therefore deserves a coatings valuation, not a food multiple. I use 12x, 15x and 18x 2025 operating profit in the SOTP scenarios below. These are research assumptions, not claimed live peer multiples. The upper end is supported by Jotun's superior growth, margin and net-cash position; the lower end recognises cyclicality, raw-material exposure and the absence of liquidity in the shares.

At the holding-company level, Orkla also differs from Investor AB and Industrivärden. Investor reported adjusted NAV of SEK 1,214.7 billion, or SEK 397 per share, at June 2026, and its reported discount to adjusted NAV in recent financial data was only a few percent. Industrivärden ended 2025 with NAV of SEK 444 per share against a share price around SEK 415, a discount of roughly 6.5%.

Those firms deserve tighter discounts because much of their NAV is continuously observable in listed securities. Orkla contains privately valued operating companies and a large unlisted associate. An Orkla discount in the low teens is defensible even if operational execution is good. A 20%-plus discount would signal either distrust of management's asset valuations or concern that weak businesses will consume value generated by the strong ones.

Current fundamentals and the live bull-bear debate

The last four reported periods show a deceleration rather than a collapse.

Q3 2025 was still reasonably healthy at the top line: revenue was NOK 17.9 billion and organic growth 4.4%, including 1.3% volume/mix. Adjusted EBIT rose 2.1%, while underlying EBIT growth in the consolidated portfolio companies was only 1.1%. This already showed that sales growth was not converting one-for-one into profit.

Full-year 2025 ended with revenue of NOK 71.5 billion, 3.3% higher than 2024. Consolidated portfolio-company adjusted EBIT increased 7.8%, associate profit rose 17%, and adjusted diluted EPS reached NOK 6.83, up 13%. The year closed with the investment-company narrative looking credible: margin repair, Jotun growth and asset disposals all supported shareholder returns.

Q1 2026 looked stronger on volume than Q3. Consolidated organic growth was 4.9%, including 3.2% volume/mix, and revenue rose 1.3% reported despite currency effects. Underlying adjusted-EBIT growth was only 3.0%. Jotun's reported contribution fell 5.8% because of currency translation and timing, even though Jotun's underlying sales and operating profit grew 9.4% and 16%.

Q2 took away the volume cushion. Consolidated portfolio-company organic growth fell to zero and underlying adjusted-EBIT growth to 2.5%. Reported group revenue fell 5.4%, largely because the stronger Norwegian krone reduced translated foreign sales. The distinction matters: reported -5.4% exaggerates the operating slowdown; organic zero accurately captures it.

Jotun rescued the earnings line. Its NOK 494 million contribution was up 17%, and adjusted EPS still rose 2.6%. Orkla explicitly attributes the EPS increase to Jotun. In rough terms, absent the NOK 73 million year-on-year increase in the Jotun contribution, group adjusted earnings would have struggled to show meaningful growth. This is an inference from Orkla's disclosed income-statement bridge, rather than a company-provided counterfactual.

The share-price reaction confirms that investors cared more about the controlled portfolio than the headline EPS increase. ORK fell roughly 6.7% on 20 August to NOK 96.30 following the report. The message from the market was clear: investors are willing to value Jotun, but they will not allow Jotun indefinitely to obscure weak internal organic growth.

The market is trading four narratives at once.

The first is whether Q2's zero organic growth is temporary. Easter phasing genuinely shifted some sales between Q1 and Q2, and Q1 organic growth was 4.9%. That supports a cyclical/timing explanation. Yet Foods' mature portfolio, Food Ingredients' bakery and plant-based weakness, Health's restructuring costs and Home & Personal Care's negative Q2 volume show that company-specific issues also exist.

My assessment is that the weakness is about half cyclical/post-inflation normalisation and half portfolio-specific. Consumers are adjusting after large price increases and retailers are exerting pressure, but Health's factory footprint, Food Ingredients' mix and mature Foods categories cannot be blamed on Easter alone.

The second narrative is Jotun. Jotun's economics are currently strong enough to change Orkla's consolidated earnings direction. In 2025 Jotun produced a 20.6% operating margin; in Q2 2026 underlying sales and operating profit grew 11% and 21%. Bulls can reasonably argue that investors underappreciate this asset because it has no exchange-traded price.

The bear response is equally sound: Jotun's raw-material costs have already risen, and Orkla's Q2 report warns that lag effects mean the full margin impact has not yet appeared. A prolonged Middle East conflict could worsen supply chains, logistics and material availability. Extrapolating 21% profit growth is unsafe.

The third narrative is India as an externally marked asset. The IPO confirms that Orkla's portfolio-company architecture can produce a listed subsidiary without losing control. Yet the current Indian market price is around 18% below the bottom of the INR 695–730 IPO price band and about 22% below the top. The public market is effectively telling Orkla that growth alone is insufficient; earnings conversion matters.

The listing also changes Orkla's accounting economics. With roughly 75% retained ownership, Orkla continues consolidating 100% of India revenue and EBIT, while external shareholders claim about 25% of equity economics. Investors should focus on attributable value, not the size of consolidated India revenue.

The fourth narrative is capital return. The NOK 6 dividend and NOK 4 billion buyback create immediate cash yield and reduce shares outstanding. Yet the extraordinary portion of the dividend cannot be capitalised as recurring income, and buybacks financed alongside rising net debt cannot continue at the same scale forever.

The bull case currently rests on specific evidence: 2024–25 underlying EBIT compounded at 12%; margin has risen 1.5 points since 2023; Jotun is growing far faster than the controlled portfolio; India provides a quoted valuation anchor; and Home & Personal Care, House Care, Snacks and HSNG show that portfolio-level improvement is possible.

The bear case rests on equally concrete evidence: H1 2026 underlying EBIT growth of only 2.7% is well below the 8–10% strategic target; Q2 organic growth is zero; Food Ingredients and Health are declining in underlying profit; several mature Nordic businesses are relying on cost control rather than volume; and leverage has risen to 2.0x EBITDA after capital returns.

There is also an expectation question. ORK at NOK 97.10 is no longer priced like a perfect execution story. The stock has fallen a long way from its 2025 year-end level and sits near the lower end of the recent range. The market has already discounted some disappointment. What remains uncertain is whether it has discounted enough.

The next hard event is Q3 2026, scheduled for 6 November. Management also plans to present ambitions for the next strategic period at a Capital Markets Day in December. Q3 will test whether Q2 was mostly Easter phasing; December should reveal whether Orkla intends to accelerate portfolio disposals, listings or capital returns.

Valuation, cash-flow passthrough, risks, and catalysts

Valuing Orkla on one blended EV/EBITDA multiple would defeat the purpose of analysing the business correctly. The controlled businesses, India, Jotun, parent cost, minority interests and net debt have different economic bases. The valuation below begins with cash conversion and then builds an explicit SOTP.

Cash-flow passthrough first. A perfectly clean five-year operating-cash-flow/net-income ratio cannot be produced from the disclosed series without mixing bases: Orkla changed its reporting structure, hydropower became discontinued, and its frequently presented “Orkla-format cash flow from operations” deducts replacement investment and therefore differs from IFRS operating cash flow. I do not substitute a false precision. The available checkpoints show IFRS operating cash flow of NOK 6.35 billion against NOK 4.90 billion net profit in 2021, about 1.30x; NOK 5.23 billion against NOK 5.27 billion in 2022, about 0.99x; and 2025 Orkla-format cash flow from operations of NOK 7.75 billion after NOK 2.68 billion of net replacement investment. The evidence does not indicate a persistent long-run failure to convert earnings to cash.

Maintenance versus growth capex is easier to see in Orkla's own cash-flow presentation than in most accounts. In 2025 net replacement investment was NOK 2.68 billion and expansion investment NOK 678 million; H1 2026 replacement investment was NOK 1.20 billion and expansion NOK 391 million. Depreciation in 2025 was NOK 2.73 billion, remarkably close to replacement investment. That means an owner-earnings adjustment of “net income + depreciation - maintenance capex” does not produce a large gap from normalised accounting earnings.

At NOK 97.10 and adjusted 2025 EPS of NOK 6.83, the headline adjusted P/E is approximately 14.2x and the earnings yield about 7.0%. Because replacement capex and depreciation are nearly equal, the owner-earnings multiple is also roughly 14x before working-capital normalisation. Depreciation of NOK 2.73 billion exceeded replacement investment of NOK 2.68 billion by only about 2% in 2025, so owner earnings and reported adjusted earnings sit close enough together that an earnings multiple remains a valid primary tool.

Cash flow before capital allocation was NOK 6.95 billion in 2025. Against the current ex-treasury market capitalisation of approximately NOK 93.4 billion, that is a historical yield around 7.4%. That measure is not a pure FCF yield in the textbook sense because Orkla's format includes financial items and dividends from associates, but it is useful for gauging cash available before acquisitions, expansion investment and shareholder distributions.

The SOTP uses 2025 adjusted EBIT for mature portfolio companies because 2026 is incomplete. Jotun uses its own 2025 operating profit. HSNG is the exception: its NOK 54 million 2025 EBIT is clearly below the current run rate, so I normalise to approximately NOK 90 million, close to twice H1 2026 adjusted EBIT of NOK 45 million.

The controlled-business inputs are based on 2025 EBIT disclosed by Orkla; Jotun is based on NOK 7.081 billion of 2025 operating profit and roughly NOK 2.0 billion net cash. Orkla's June 2026 net debt is NOK 20.683 billion. The holding-company discounts, valuation multiples and minority-interest reserve are my research assumptions, not company guidance.

The multiple assumptions behind the controlled portfolio are intentionally differentiated. Foods receives 11–15x EBIT because it is a mature but resilient branded franchise. Snacks receives 12–16x given BUBS and stronger current profit growth. Food Ingredients receives 9–13x because its margin and current organic trend are weaker. Health gets 9–13x until restructuring proves itself. Home & Personal Care gets 10–14x because its ROCE is high despite mature sales. India gets 14–18x EBIT, with its quoted market capitalisation providing an external reality check. These are analyst assumptions rather than peer multiples carried from third-party screens.

India's live price supports rather than contradicts the base assumption. At INR 570.30 and roughly 137.0 million shares, Orkla India is worth around INR 78.1 billion, or about NOK 7.6 billion at roughly INR 10.29 per NOK. The SOTP base enterprise value of NOK 7.8 billion is therefore close to the market's observable equity value, subject to the subsidiary's own net-debt position.

Jotun drives much more of the valuation spread. At 12x 2025 operating profit plus net cash, the entire company is worth about NOK 87 billion and Orkla's stake roughly NOK 37 billion. At 15x the stake is about NOK 46 billion; at 18x it reaches NOK 55 billion. Jotun has no traded market price, so none of these figures should be called “market value.” They are estimates derived from a coatings-company multiple applied to Jotun's own earnings.

The upper half of that range is not unreasonable given Jotun's 20.6% operating margin, net-cash position and Q2 underlying sales/profit growth of 11%/21%. The conservative end recognises that coatings are cyclically exposed and that raw-material inflation is likely to pressure upcoming margins.

The parent-cost deduction is also important. Orkla ASA and Business Services reported adjusted EBIT of -NOK 65 million in Q2, compared with -NOK 75 million a year earlier. Capitalising a roughly NOK 250–300 million annual parent cost removes NOK 3–4 billion of value. Shared services need to create at least that much incremental portfolio value just to break even.

The minority-interest reserve prevents a subtler double count. Orkla consolidates 100% of companies it controls even when outside shareholders own part of them, most visibly the 25% now held outside Orkla in India. Using full subsidiary EBIT to calculate enterprise value and then giving all resulting equity value to ORK shareholders would overstate NAV. The reserve of NOK 3–5 billion is an estimate reflecting India plus other non-controlling interests. Orkla reported NOK 584 million of profit attributable to non-controlling interests in 2025.

Before the holding-company discount, the base SOTP is NOK 123.4 per share. The market price of NOK 97.10 is about a 21% discount to that estimated raw NAV. That sounds large beside Investor AB's recent low-single-digit reported discount and Industrivärden's roughly 6.5% end-2025 discount, but Orkla's NAV is much less observable. Applying a 12% structural discount produces a base investable value around NOK 108.6.

The current discount is partly genuine and partly compensation for valuation uncertainty: investors cannot see a market price for Jotun and cannot yet assume that every portfolio company deserves a premium branded-goods multiple.

The three valuation scenarios can be framed more directly:

†Assumes approximately NOK 4 annual ordinary dividend and terminal value reached after three years. The NOK 2 additional dividend paid in 2026 is not treated as recurring. This is valuation-scenario analysis within a research framework, not investment advice. The ordinary-versus-additional dividend distinction is disclosed by Orkla.

Expectation-gap analysis centres on three numbers. The first is organic growth in the consolidated portfolio. A Q3 rebound to 2–4% would validate management's Easter explanation; another quarter around zero would make structural weakness the default interpretation. The second is Health and Food Ingredients EBIT: both need to stop declining. The third is Jotun's margin response to higher raw-material costs. Orkla has already warned that the lagged cost effect is coming.

India is now a fourth visible expectation gauge. Its public share price gives investors a daily market vote on Orkla's growth-business valuation. The fact that it trades materially below its IPO price band constrains how aggressively the parent can mark it in an SOTP.

The independent margin-of-safety check is less favourable than the base-case upside suggests. Current NOK 97.10 is about 23% above the conservative investable value of NOK 79.1. Margin of safety against the conservative case is zero.

The most fragile base-case assumption is that the holding-company discount stabilises near 12% while controlled growth recovers. If only 70% of the expected discount improvement/operational re-rating is realised, a reasonable stress value falls into roughly the NOK 100–103 area rather than NOK 108.6. That leaves limited upside from the current price.

The flat-earnings test is harsher. Assume adjusted earnings do not grow for three years, the valuation multiple remains unchanged and Orkla pays only the NOK 4 ordinary dividend. The annual cash yield is about 4.1% at NOK 97.10. Norway's 10-year government yield was about 4.43% on 24 August 2026. Under those assumptions, there is no capital appreciation and the dividend yield is below the government-bond yield. On that test there is no margin of safety at this price.

Margin-of-safety sufficiency verdict: none.

That verdict does not mean the enterprise is weak. It means the price does not compensate an investor for the conservative scenario under a strict permanent-capital-loss discipline.

The principal risks are more concentrated than a generic risk list would suggest.

The first is structural volume erosion in mature Nordic brands. Probability is medium and impact high. The observable signal would be consolidated organic growth below 1% for two or more quarters, especially if Foods' prioritised categories also turn negative. The transmission path is volume decline → weaker factory utilisation and promotional intensity → lower margins → lower controlled-business multiples. Q2 already contains early evidence in Foods and several household categories.

The second is Jotun normalisation. Probability is medium and impact high because Jotun accounts for roughly NOK 37–55 billion of my SOTP. The observable indicators are Jotun operating-profit growth, gross margin, raw-material prices and Middle East disruption. Orkla says higher material costs have not yet fully flowed through earnings. A 25–30% fall in Jotun EBIT combined with a lower coatings multiple could remove NOK 15–20 per ORK share of estimated NAV.

The third is failed Health restructuring. Probability is medium and impact medium. Health's H1 underlying EBIT fell about 20%, ROCE is only around 8%, and three plants still need to close by end-2027. If cost savings arrive later than planned while omega-3 inputs remain expensive, the segment's currently assumed 9–13x EBIT range would be too generous.

The fourth is capital-allocation slippage. Probability is low-to-medium and impact high over a long horizon. Net debt is already NOK 20.7 billion after large distributions, and the completed buyback price is above today's market. A sequence of premium-priced acquisitions financed with more debt while organic growth remains weak would destroy the logic of the investment-company model.

The fifth is governance concentration following succession. Probability of a disruptive event is low, but impact could be medium. The Canica/Hagen arrangement still controls 25.41%, and the new chair represents continuity with that ownership. The indicator is not insider ownership itself; it is whether future asset sales, acquisitions and related-party arrangements remain transparently priced for all shareholders.

Positive catalysts over the next 12 months are concrete: Q3 organic growth rebounding above 2%; Health's EBIT decline moderating; Food Ingredients returning to positive volume; continued BUBS distribution growth after the European Candy acquisition; Jotun maintaining double-digit underlying sales/profit momentum despite raw-material inflation; and December's Capital Markets Day announcing credible portfolio exits or additional listed-value references.

Negative catalysts are the mirror image: another quarter of near-zero organic growth, a Health restructuring delay, Jotun margin compression, India continuing to derate, leverage moving decisively above 2.5x EBITDA, or management using balance-sheet capacity for acquisitions before existing weak units recover.

The practical tracking dashboard is:

Current figures and strategic targets are from Orkla's Q2 report; next earnings date is Orkla's financial calendar.

The most important blind spots are valuation rather than accounting mysteries. Jotun has no traded price, so its stake value is necessarily estimated. Orkla does not publish a continuous historical NAV series, so the holdco discount cannot be back-tested with the precision available for Investor AB. A clean five-year cash-conversion ratio is impaired by presentation and perimeter changes. India reports to Indian exchanges under Ind AS and in INR while Orkla reports it under IFRS and calendar-year NOK, creating differences even before currency translation. Finally, Orkla does not publish enough deal-level post-acquisition returns to calculate a rigorous acquisition IRR for every portfolio purchase.

Cross-synthesis, pre-mortem, and final research conclusion

Looking vertically, the capability Orkla has actually proven is adaptation through capital allocation. A mining business became an industrial conglomerate; the conglomerate became a branded-goods company; the branded-goods company is becoming an industrial investment company. That sequence spans far too long to dismiss as one favourable cycle. The group has repeatedly shown that it can dispose of assets when the strategic centre changes, buy positions in consumer categories and maintain a stable ownership framework through major structural change.

The past success did not come from one timeless moat. Different eras contributed different things. Mining and industrial investment created capital. The Nordic consumer consolidation of the 1980s and 1990s supplied brand positions. Acquisition-driven expansion supplied scale. The benign post-2013 consumer valuation environment rewarded defensiveness. Inflation after 2021 gave Orkla an opportunity to prove pricing and cost discipline, while simultaneously exposing weak businesses. Jotun supplied a major independent source of value throughout much of this period.

The capability that matters now is narrower: can the parent allocate capital between independent portfolio companies better than public-market investors could allocate it themselves? That is the economic justification for a holding company. The answer remains unproven.

The 2024–25 evidence is favourable. Underlying adjusted EBIT compounded at 12%, the consolidated margin improved 1.5 points and ROCE rose toward 13%. Portfolio actions were meaningful rather than cosmetic: hydropower was sold, India was listed, buybacks reduced the share count and acquisitions were concentrated in identified growth categories.

The first half of 2026 is the warning. Margin repair has moved faster than revenue quality. Controlled-company underlying EBIT growth fell to 2.7%, Q2 organic sales stalled and several major businesses relied on mix and cost reduction rather than volume. Costs can be removed once; a consumer franchise must eventually sell more product.

Horizontally, Orkla's advantage against global consumer groups is local density. It does not possess Unilever's worldwide marketing economics, and its overall controlled-company margin is much lower. It does, however, own brands that are difficult to displace in small Nordic categories, and it can manage them with local rather than global decision-making. Against Nomad Foods, Orkla has broader categories, a stronger asset balance and Jotun, which reduces dependence on one European frozen-food cycle.

The disadvantage is portfolio heterogeneity. Food Ingredients should not receive the same multiple as a fast-growing confectionery brand. Health currently does not deserve the multiple of a clean consumer-health compounder. India should not be valued as a hypothetical emerging-market IPO because it now has a real share price. Jotun should not be buried inside an Orkla P/E because coatings economics are different from packaged food.

This is why SOTP matters so much. My base raw NAV of NOK 123.4 per share implies that today's NOK 97.10 price is roughly 21% below a no-discount asset value. But the raw NAV contains estimates, especially NOK 46 billion for the Jotun stake. A 12% holding-company discount lowers base investable value to roughly NOK 108.6. The apparent undervaluation then shrinks to about 11%. That is real, but not large enough to ignore operational risk.

The current market is most likely misjudging two things in opposite directions.

It may be underestimating Jotun. A business producing a 20.6% operating margin, net cash and Q2 underlying growth of 11% in sales and 21% in operating profit would probably command substantial value if publicly traded. A large share of Orkla's market capitalisation can be economically explained by Jotun alone under reasonable coatings multiples.

At the same time, the market may still be too patient with some controlled assets. Foods' prioritised categories are growing, but the mature portfolio is shrinking. Health is in a multi-year factory restructuring. Food Ingredients' Bakery and Plant Based operations are weak. The assumption that every business will eventually reach management's target returns is not yet supported by the current data.

India tells a useful story about price discovery. The parent successfully created a quoted marker while retaining 75%, but the Indian market has subsequently marked that asset below its IPO range. That is exactly how the investment-company model should be tested: external capital should challenge internal valuations.

The listing does not by itself imply that Orkla intends to break itself up completely. Retaining 75% points in the opposite direction: Orkla still wants control. It does, however, establish a precedent. Businesses can have separate capital-market identities while Orkla remains an owner. A second listing or large divestment would make the “investment company” description more than an organisational chart.

The use of India IPO proceeds cannot be traced dollar-for-dollar into subsequent Orkla capital returns from the public disclosures reviewed. Because the IPO was an offer for sale, proceeds accrued to selling shareholders rather than funding Orkla India itself. Orkla later paid a large dividend and completed a NOK 4 billion buyback, but attributing those distributions specifically to India proceeds would be speculation.

For the next year, the critical variable is controlled-company organic growth. A recovery to 2–4% would let investors treat Q2 as a temporary post-Easter trough. Continued zero growth would change the question from “when does volume recover?” to “what needs to be sold?” The November Q3 report is therefore more important than another quarter of Jotun outperformance.

Over three years, portfolio discipline matters more than one quarter. Health must close its factories and restore return on capital. Food Ingredients must show that acquisition spending produces organic and margin improvement. BUBS and European Candy need to turn distribution growth into returns on the acquisition price. India must prove that digital investment expands EBIT rather than simply revenue.

Over five years, the key variable is whether Orkla can reduce the structural holding-company discount. Investor AB and Industrivärden show that a Nordic holding company does not automatically deserve a 20% discount; transparent NAV, credible capital allocation and proven compounding can support single-digit discounts. Orkla will need more externally priced assets, fewer structurally weak businesses and a clear record of return on acquisitions to earn that treatment.

The portfolio becomes a good deal more attractive if three things happen together: controlled-company organic growth returns above 3%, Health and Food Ingredients move back to sustainable EBIT growth, and the share price remains near today's level or lower while Jotun continues to compound. A lower share price without fundamental deterioration would also create the missing margin of safety.

The thesis should be overturned in the negative direction if two consecutive quarters show sub-1% consolidated organic growth, Jotun operating profit turns materially negative year on year because its margin normalises, and net debt exceeds 2.5x EBITDA while Orkla continues large acquisitions. Those conditions would show that the parent is simultaneously losing operating momentum, asset quality and financial flexibility.

Bull and bear reasons

Bull reasons:

• 2024–25 underlying adjusted EBIT in the consolidated portfolio companies compounded at 12%, while the rolling margin improved 1.5 percentage points, proving that the 2023 portfolio-accountability model has produced measurable operational gains.
• Jotun's 2025 operating margin was 20.6%, and Q2 2026 underlying sales and operating profit grew 11% and 21%, creating substantial hidden value that is not visible in Orkla revenue.
• India is now publicly quoted, giving investors an external reference for one growth asset while Orkla retains approximately 75% ownership and control.
• Home & Personal Care's rolling ROCE of roughly 26% and Snacks' double-digit underlying EBIT growth show that some independently managed businesses are improving even in a weak consumer quarter.
• The base SOTP produces raw NAV around NOK 123 per share versus NOK 97.10 in the market, leaving a wide estimated NAV discount before applying a holding-company haircut. Inputs are based on issuer-reported segment and Jotun earnings.

Bear reasons:

• Q2 consolidated organic growth was zero and H1 underlying EBIT growth only 2.7%, well below the 8–10% strategic target.
• Food Ingredients' Q2 underlying EBIT fell 6.3% and Health's H1 underlying EBIT fell almost 20%, meaning two businesses once classified for growth are currently detracting from earnings quality.
• Orkla itself says Q2 adjusted-EPS growth was driven by Jotun, making current group earnings momentum unusually dependent on an associate that Orkla does not control.
• Net debt increased to NOK 20.7 billion, or 2.0x EBITDA, after the company combined large dividends and buybacks with acquisitions.
• India trades well below its IPO price band, warning that public investors are unwilling to pay an unconstrained growth premium while margins are declining.

Pre-mortem: where might I be wrong

The first concrete failure script begins in the mature Nordic portfolio. Through 2027 retailers push private-label products and keep promotional intensity high after the inflation cycle. Foods' total volume/mix stays around -2% rather than recovering, Food Ingredients remains weak and Health factory savings arrive a year late. Consolidated portfolio adjusted-EBIT margin falls from the current rolling 10.5% toward 9%, while investors cut mature-business EBIT multiples from the base 11–14x range toward 8–10x. The estimated raw NAV drops below NOK 100 and the holding-company discount widens toward 25%. Even if Jotun remains healthy, ORK could trade in the NOK 60–70 range.

The second script is an asset-correlation shock. During 2027 prolonged Middle East disruption and commodity inflation raise coatings raw-material costs faster than Jotun can reprice; its operating profit falls 25–30% from the 2025 level and investors value it at 12x rather than 15–18x. At the same time the Nordic consumer portfolio shows no organic growth, forcing Orkla to spend on promotions and restructuring while net debt remains near or above 2.5x EBITDA. Jotun's implied contribution to ORK NAV could fall by more than NOK 15 per share while the controlled-business multiple also compresses. A move toward NOK 50–60 would then be possible, representing roughly 40–50% downside from the current price. The scenario is not the base case, but its transmission mechanism is economically coherent given Orkla's current asset mix. Jotun's own current raw-material warnings and Orkla's leverage disclosure establish the underlying risk variables.

Final research conclusion

Orkla shows with unusual clarity why accounting form and economic substance must be separated. The consolidated consumer portfolio is currently a roughly NOK 70 billion-revenue business with improving margins but weak organic momentum. Jotun is a separate, unlisted coatings asset whose economics are currently superior to almost everything Orkla controls. India has become a listed controlled subsidiary and now provides external price discovery. Treating these pieces as one operating-company multiple hides the most important facts.

At NOK 97.10, I think the market already prices in a fair amount of Q2 disappointment but does not offer enough protection against the conservative scenario. My base SOTP is higher than the share price, and a raw NAV calculation produces real apparent upside. After applying a reasonable holding-company discount, base fair value falls to roughly NOK 109. The current price is therefore within a defensible holding zone rather than a compelling entry zone. The strongest reason to own the shares is Jotun plus optionality from portfolio simplification. The strongest reason to wait is that Q2 showed the controlled companies are not yet producing the organic growth needed to validate the investment-company architecture.

The investment case improves materially when the price supplies the margin of safety that the current operating performance does not.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: value / dividend / event-driven

【Investment rating】

• Rating: Hold
• One-line thesis: Jotun and portfolio optionality support NAV, but flat controlled-company organic growth leaves too little conservative-case margin of safety.
• Ideal buy price: see dedicated line below.
• Acceptable hold price: NOK 92–125, corresponding approximately to ±15% around the NOK 108.6 base investable value.
• Clearly overvalued price: NOK 155 and above, at least 10% above the NOK 140.5 optimistic scenario.
• Current-price classification: acceptable hold.
• Whether to wait for a better price: yes. The disciplined entry zone is NOK 60–63, or a somewhat higher price only if consolidated organic growth sustainably returns above 3%, Health and Food Ingredients resume EBIT growth and Jotun remains strong. The opportunity cost is missing a faster-than-expected narrowing of the holding-company discount after the December strategy update.
• Target holding horizon: 3–5 years.
• Expected annualized return: conservative about -2%, base about 7.5%, optimistic about 16%, assuming three years to terminal value plus a NOK 4 annual ordinary dividend.
• Max-loss risk: roughly 40–50% in the pre-mortem case where Jotun profit falls 25–30%, controlled-company margins retreat toward 9%, leverage rises and the holding-company discount widens toward 25%.
• Reassessment-trigger signals: consolidated organic growth below 1% for two consecutive quarters; net debt/EBITDA above 2.5x; Orkla Health adjusted-EBIT margin below 9% without a credible restructuring bridge; Jotun underlying operating-profit growth turning materially negative; or Food Ingredients remaining in underlying EBIT decline through 2027.

【Ideal Buy Price】60–63 NOK

Basis: the conservative investable SOTP is approximately NOK 79 per share; NOK 63 is roughly 20% below that value, which is the minimum discount I treat as a genuine margin of safety. The lower end adds additional protection against uncertainty in Jotun's unlisted valuation.

【Valuation Range】

• current: 97.10 NOK (close as of 2026-08-24)
• bear (conservative · ideal buy zone): [60, 63]
• base (fair · acceptable hold zone): [92, 125]
• bull (optimistic · above the clearly-overvalued line): [155, 170]

The primary source hierarchy for this report is Orkla's Q2 2026 report and company disclosures; Orkla's 2025 annual information and financial calendar; Jotun's own 2025 results and financial publications; the Orkla India prospectus and IPO disclosures; and issuer materials from Unilever, Danone, Nomad Foods, PPG, AkzoNobel, Investor AB and Industrivärden. Market-price sources are used only where an exchange close or live listed valuation was required.

Other tickers mentioned

• ULVR.LSE: Unilever is the global branded-consumer reference for brand scale, marketing intensity and operating margin.
• BN.PA: Danone provides a European consumer-staples benchmark with current positive volume/mix growth and a low-teens recurring operating margin.
• NOMD.US: Nomad Foods is the closer European packaged-food stress comparison for volume weakness and input-cost pressure.
• PPG.US: PPG is a listed global coatings reference used to benchmark Jotun's growth and profitability.
• AKZA.AS: AkzoNobel is a European listed coatings reference for Jotun's operating economics.
• INVE-B.ST: Investor AB illustrates the low NAV discount achievable by a transparent, established Nordic investment company.
• INDU-C.ST: Industrivärden provides a second Nordic holding-company reference for observable NAV-discount discipline.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.